Can GLP-1 medication reduce the risk of Alzheimer’s Disease?
GLP-1 receptor agonists such as Semeglutide (Ozempic® and Wegovy®) are becoming a household name for weight-loss treatments for clinically obese patients, with 82% of adults having heard about GLP-1 medications. However, the benefits of GLP-1 medications are not just limited to
Is the term ‘obese’ outdated? New global report says yes!
With the huge success of the once-weekly injectable weight-loss treatments such as Ozempic® and Wegovy® over recent years to help combat the global ‘obesity’ epidemic; medical professionals have called for a new definition of the term ‘obese’. Despite individuals with higher